Costimulation-adhesion blockade is superior to cyclosporine a and prednisone immunosuppressive therapy for preventing rejection of differentiated human embryonic stem cells following transplantation

Bruno C. Huber, Julia D. Ransohoff, Katherine J. Ransohoff, Johannes Riegler, Antje Ebert, Kazuki Kodo, Yongquan Gong, Veronica Sanchez-Freire, Devaveena Dey, Nigel G. Kooreman, Sebastian Diecke, Wendy Y. Zhang, Justin Odegaard, Shijun Hu, Joseph D. Gold, Robert C. Robbins, Joseph C. Wu

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Rationale: Human embryonic stem cell (hESC) derivatives are attractive candidates for therapeutic use. The engraft-ment and survival of hESC derivatives as xenografts or allografts require effective immunosuppression to prevent immune cell infiltration and graft destruction. Objective: To test the hypothesis that a short-course, dual-agent regimen of two costimulation-adhesion blockade agents can induce better engraftment of hESC derivatives compared to current immunosuppressive agents. Methods and Results: We transduced hESCs with a double fusion reporter gene construct expressing firefly luciferase (Fluc) and enhanced green fluorescent protein, and differentiated these cells to endothelial cells (hESC-ECs). Reporter gene expression enabled longitudinal assessment of cell engraftment by bioluminescence imaging. Costimu-lation- adhesion therapy resulted in superior hESC-EC and mouse EC engraftment compared to cyclosporine therapy in a hind limb model. Costimulation-adhesion therapy also promoted robust hESC-EC and hESC-derived car-diomyocyte survival in an ischemic myocardial injury model. Improved hESC-EC engraftment had a cardio-protective effect after myocardial injury, as assessed by magnetic resonance imaging. Mechanistically, costimulation-adhesion therapy is associated with systemic and intragraft upregulation of T-cell immunoglobulin and mucin domain 3 (TIM3) and a reduced proinflammatory cytokine profile. Conclusions: Costimulation-adhesion therapy is a superior alternative to current clinical immu-nosuppressive strategies for preventing the post-transplant rejection of hESC derivatives. By extending the window for cellular engraftment, costimulation-adhesion therapy enhances functional preservation following ischemic injury. This regimen may function through a TIM3-dependent mechanism.

Original languageEnglish
Pages (from-to)2354-2363
Number of pages10
JournalStem Cells
Volume31
Issue number11
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Immunosuppressive Agents
Prednisone
Cyclosporine
Mucin-3
Therapeutics
Reporter Genes
Wounds and Injuries
Human Embryonic Stem Cells
Firefly Luciferases
T-Lymphocytes
Graft Rejection
Therapeutic Uses
Heterografts
Immunosuppression
Allografts
Up-Regulation
Extremities
Endothelial Cells
Magnetic Resonance Imaging

Keywords

  • Costimulation blockade
  • Embryonic stem cells
  • Endothelial cells
  • Immune tolerance
  • Immunosuppressive drugs
  • Myocardial infarction

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Molecular Medicine

Cite this

Costimulation-adhesion blockade is superior to cyclosporine a and prednisone immunosuppressive therapy for preventing rejection of differentiated human embryonic stem cells following transplantation. / Huber, Bruno C.; Ransohoff, Julia D.; Ransohoff, Katherine J.; Riegler, Johannes; Ebert, Antje; Kodo, Kazuki; Gong, Yongquan; Sanchez-Freire, Veronica; Dey, Devaveena; Kooreman, Nigel G.; Diecke, Sebastian; Zhang, Wendy Y.; Odegaard, Justin; Hu, Shijun; Gold, Joseph D.; Robbins, Robert C.; Wu, Joseph C.

In: Stem Cells, Vol. 31, No. 11, 2013, p. 2354-2363.

Research output: Contribution to journalArticle

Huber, BC, Ransohoff, JD, Ransohoff, KJ, Riegler, J, Ebert, A, Kodo, K, Gong, Y, Sanchez-Freire, V, Dey, D, Kooreman, NG, Diecke, S, Zhang, WY, Odegaard, J, Hu, S, Gold, JD, Robbins, RC & Wu, JC 2013, 'Costimulation-adhesion blockade is superior to cyclosporine a and prednisone immunosuppressive therapy for preventing rejection of differentiated human embryonic stem cells following transplantation', Stem Cells, vol. 31, no. 11, pp. 2354-2363. https://doi.org/10.1002/stem.1501
Huber, Bruno C. ; Ransohoff, Julia D. ; Ransohoff, Katherine J. ; Riegler, Johannes ; Ebert, Antje ; Kodo, Kazuki ; Gong, Yongquan ; Sanchez-Freire, Veronica ; Dey, Devaveena ; Kooreman, Nigel G. ; Diecke, Sebastian ; Zhang, Wendy Y. ; Odegaard, Justin ; Hu, Shijun ; Gold, Joseph D. ; Robbins, Robert C. ; Wu, Joseph C. / Costimulation-adhesion blockade is superior to cyclosporine a and prednisone immunosuppressive therapy for preventing rejection of differentiated human embryonic stem cells following transplantation. In: Stem Cells. 2013 ; Vol. 31, No. 11. pp. 2354-2363.
@article{59cadbb9b99b4749b748def72e120414,
title = "Costimulation-adhesion blockade is superior to cyclosporine a and prednisone immunosuppressive therapy for preventing rejection of differentiated human embryonic stem cells following transplantation",
abstract = "Rationale: Human embryonic stem cell (hESC) derivatives are attractive candidates for therapeutic use. The engraft-ment and survival of hESC derivatives as xenografts or allografts require effective immunosuppression to prevent immune cell infiltration and graft destruction. Objective: To test the hypothesis that a short-course, dual-agent regimen of two costimulation-adhesion blockade agents can induce better engraftment of hESC derivatives compared to current immunosuppressive agents. Methods and Results: We transduced hESCs with a double fusion reporter gene construct expressing firefly luciferase (Fluc) and enhanced green fluorescent protein, and differentiated these cells to endothelial cells (hESC-ECs). Reporter gene expression enabled longitudinal assessment of cell engraftment by bioluminescence imaging. Costimu-lation- adhesion therapy resulted in superior hESC-EC and mouse EC engraftment compared to cyclosporine therapy in a hind limb model. Costimulation-adhesion therapy also promoted robust hESC-EC and hESC-derived car-diomyocyte survival in an ischemic myocardial injury model. Improved hESC-EC engraftment had a cardio-protective effect after myocardial injury, as assessed by magnetic resonance imaging. Mechanistically, costimulation-adhesion therapy is associated with systemic and intragraft upregulation of T-cell immunoglobulin and mucin domain 3 (TIM3) and a reduced proinflammatory cytokine profile. Conclusions: Costimulation-adhesion therapy is a superior alternative to current clinical immu-nosuppressive strategies for preventing the post-transplant rejection of hESC derivatives. By extending the window for cellular engraftment, costimulation-adhesion therapy enhances functional preservation following ischemic injury. This regimen may function through a TIM3-dependent mechanism.",
keywords = "Costimulation blockade, Embryonic stem cells, Endothelial cells, Immune tolerance, Immunosuppressive drugs, Myocardial infarction",
author = "Huber, {Bruno C.} and Ransohoff, {Julia D.} and Ransohoff, {Katherine J.} and Johannes Riegler and Antje Ebert and Kazuki Kodo and Yongquan Gong and Veronica Sanchez-Freire and Devaveena Dey and Kooreman, {Nigel G.} and Sebastian Diecke and Zhang, {Wendy Y.} and Justin Odegaard and Shijun Hu and Gold, {Joseph D.} and Robbins, {Robert C.} and Wu, {Joseph C.}",
year = "2013",
doi = "10.1002/stem.1501",
language = "English",
volume = "31",
pages = "2354--2363",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Costimulation-adhesion blockade is superior to cyclosporine a and prednisone immunosuppressive therapy for preventing rejection of differentiated human embryonic stem cells following transplantation

AU - Huber, Bruno C.

AU - Ransohoff, Julia D.

AU - Ransohoff, Katherine J.

AU - Riegler, Johannes

AU - Ebert, Antje

AU - Kodo, Kazuki

AU - Gong, Yongquan

AU - Sanchez-Freire, Veronica

AU - Dey, Devaveena

AU - Kooreman, Nigel G.

AU - Diecke, Sebastian

AU - Zhang, Wendy Y.

AU - Odegaard, Justin

AU - Hu, Shijun

AU - Gold, Joseph D.

AU - Robbins, Robert C.

AU - Wu, Joseph C.

PY - 2013

Y1 - 2013

N2 - Rationale: Human embryonic stem cell (hESC) derivatives are attractive candidates for therapeutic use. The engraft-ment and survival of hESC derivatives as xenografts or allografts require effective immunosuppression to prevent immune cell infiltration and graft destruction. Objective: To test the hypothesis that a short-course, dual-agent regimen of two costimulation-adhesion blockade agents can induce better engraftment of hESC derivatives compared to current immunosuppressive agents. Methods and Results: We transduced hESCs with a double fusion reporter gene construct expressing firefly luciferase (Fluc) and enhanced green fluorescent protein, and differentiated these cells to endothelial cells (hESC-ECs). Reporter gene expression enabled longitudinal assessment of cell engraftment by bioluminescence imaging. Costimu-lation- adhesion therapy resulted in superior hESC-EC and mouse EC engraftment compared to cyclosporine therapy in a hind limb model. Costimulation-adhesion therapy also promoted robust hESC-EC and hESC-derived car-diomyocyte survival in an ischemic myocardial injury model. Improved hESC-EC engraftment had a cardio-protective effect after myocardial injury, as assessed by magnetic resonance imaging. Mechanistically, costimulation-adhesion therapy is associated with systemic and intragraft upregulation of T-cell immunoglobulin and mucin domain 3 (TIM3) and a reduced proinflammatory cytokine profile. Conclusions: Costimulation-adhesion therapy is a superior alternative to current clinical immu-nosuppressive strategies for preventing the post-transplant rejection of hESC derivatives. By extending the window for cellular engraftment, costimulation-adhesion therapy enhances functional preservation following ischemic injury. This regimen may function through a TIM3-dependent mechanism.

AB - Rationale: Human embryonic stem cell (hESC) derivatives are attractive candidates for therapeutic use. The engraft-ment and survival of hESC derivatives as xenografts or allografts require effective immunosuppression to prevent immune cell infiltration and graft destruction. Objective: To test the hypothesis that a short-course, dual-agent regimen of two costimulation-adhesion blockade agents can induce better engraftment of hESC derivatives compared to current immunosuppressive agents. Methods and Results: We transduced hESCs with a double fusion reporter gene construct expressing firefly luciferase (Fluc) and enhanced green fluorescent protein, and differentiated these cells to endothelial cells (hESC-ECs). Reporter gene expression enabled longitudinal assessment of cell engraftment by bioluminescence imaging. Costimu-lation- adhesion therapy resulted in superior hESC-EC and mouse EC engraftment compared to cyclosporine therapy in a hind limb model. Costimulation-adhesion therapy also promoted robust hESC-EC and hESC-derived car-diomyocyte survival in an ischemic myocardial injury model. Improved hESC-EC engraftment had a cardio-protective effect after myocardial injury, as assessed by magnetic resonance imaging. Mechanistically, costimulation-adhesion therapy is associated with systemic and intragraft upregulation of T-cell immunoglobulin and mucin domain 3 (TIM3) and a reduced proinflammatory cytokine profile. Conclusions: Costimulation-adhesion therapy is a superior alternative to current clinical immu-nosuppressive strategies for preventing the post-transplant rejection of hESC derivatives. By extending the window for cellular engraftment, costimulation-adhesion therapy enhances functional preservation following ischemic injury. This regimen may function through a TIM3-dependent mechanism.

KW - Costimulation blockade

KW - Embryonic stem cells

KW - Endothelial cells

KW - Immune tolerance

KW - Immunosuppressive drugs

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=84887958536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887958536&partnerID=8YFLogxK

U2 - 10.1002/stem.1501

DO - 10.1002/stem.1501

M3 - Article

C2 - 24038578

AN - SCOPUS:84887958536

VL - 31

SP - 2354

EP - 2363

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 11

ER -